Document is current
Any future updates will be listed below
-
Authors
Zeig-Owens, Rachel
Goldfarb, David G.
Luft, Benjamin J. https://orcid.org/0000-0001-9008-7004
Yang, Xiaohua
Murata, Kazunori https://orcid.org/0000-0002-5921-4201
Ramanathan, Lakshmi
Thoren, Katie
Doddi, Sital
Shah, Urvi A. https://orcid.org/0000-0001-8419-1091
Mueller, Alexandra K.
Hall, Charles B.
Giricz, Orsi https://orcid.org/0000-0002-1328-3682
Verma, Amit
Prezant, David J.
Landgren, Ola https://orcid.org/0000-0001-6485-4839
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | CDC | National Institute for Occupational Safety and Health (200-2011-39383, 200-2011-39378, 200-2017-93326, 200-2017-93426, U01 OH011869, 200-2011-39383, 200-2011-39378, 200-2017-93326, 200-2017-93426, 200-2017-93432, U01 OH011869, 200-2017-93432, 200-2011-39383, 200-2011-39378, 200-2017-93326, 200-2017-93426, 200-2011-39383, 200-2011-39378, 200-2017-93326, 200-2017-93426, U01 OH011869, U01 OH011869, U01 OH011475, 200-2011-39383, 200-2011-39378, 200-2017-93326, 200-2017-93426, U01 OH011869, U01 OH011475, U01 OH011869, U01 OH011475))
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, U.S. Department of Health & Human Services | NIH | National Cancer Institute, U.S. Department of Health & Human Services | NIH | National Cancer Institute, U.S. Department of Health & Human Services | NIH | National Cancer Institute, U.S. Department of Health & Human Services | NIH | National Cancer Institute, P30 CA013330, P30 CA013330)
- License Information
-
More Information
Article History
Received: 25 March 2022
Revised: 13 July 2022
Accepted: 15 July 2022
First Online: 22 August 2022
Competing interests
: Ola Landgren has received grant support from the National Cancer Institute/National Institutes of Health, Food and Drug Administration, Leukemia and Lymphoma Society (LLS), Rising Tide Foundation, Memorial Sloan Kettering Cancer Center, Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Paula and Rodger Riney Foundation, Perelman Family Foundation, Amgen, Celgene, Janssen, Takeda, Glen- mark, Seattle Genetics, and Karyopharm; has received honoraria for scientific talks/participated in advisory boards for Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, and Pfzer; and served on Independent Data Monitoring Committees for international randomized trials by Takeda, Merck, Janssen, and Theradex. Urvi A. Shah has received support from the following: Honoraria: Janssen, ACCC, MJH Life Sciences. Research funding to the institution: Janssen, Celgene/BMS, Grants: Parker Institute for Cancer Immunotherapy, International Myeloma Society, Paula and Rodger Riney Foundation, Allen Foundation Inc, HealthTree Foundation, Janssen, Celgene/BMS, MSK Paul Calabresi Career Development Award for Clinical Oncology K12CA184746. All other authors declare no competing interests.
